The Aspergillosis market report also offers comprehensive insights into the Aspergillosis market size, share, Aspergillosis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Aspergillosis market size growth forward.
Some of the key highlights from the Aspergillosis Market Insights Report:
Several key pharmaceutical companies, including Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, ImmuPharma, Takis, and others, are developing novel products to improve the Aspergillosis treatment outlook.
In 2023, the Aspergillosis market in the 7MM was valued at around USD 2,606 million, with expectations to grow at a compound annual growth rate (CAGR) of approximately 11% by 2034.
In 2023, the US reported approximately 568 thousand cases of aspergillosis, with allergic bronchopulmonary aspergillosis (ABPA) accounting for 92% of these cases and chronic pulmonary aspergillosis (CPA) making up only 2%. Both forms are expected to see an increase in prevalence during the forecast period.
In 2023, the UK had a significant share of diagnosed prevalent aspergillosis cases among the EU4 and the UK, reporting around 179 thousand cases, while Spain had the lowest prevalence with nearly 67 thousand cases. This difference underscores the UK’s leading position in the regional aspergillosis landscape, in contrast to Spain’s much smaller case load.
Key challenges in the Aspergillosis market include limited treatment options for resistant strains, the impact of reimbursement policies on drug accessibility, and the ongoing need for affordable and effective treatments, as well as improved diagnostic capabilities.
The diagnosed prevalence of Aspergillosis has been gradually increasing, driven by higher rates among immunocompromised individuals, the rise in chronic diseases, advancements in treatment and diagnostics, and greater awareness. In 2023, there were an estimated 1,213 thousand diagnosed cases of Aspergillosis across the 7MM.
Aspergillosis is a major health concern in the United States, with its prevalence rising over the past decades. The US alone accounted for 33% of cases in 2023, followed by Japan and the UK. DelveInsight’s analysis reveals that allergic bronchopulmonary aspergillosis (ABPA) is the most prevalent type of Aspergillosis in the 7MM, surpassing chronic pulmonary aspergillosis (CPA) and invasive aspergillosis (IA).
The presence of affordable generics and off-label therapies, such as Voriconazole and Caspofungin, poses a challenge to the market growth of new drugs due to their cost-effectiveness and accessibility, which could hinder the adoption of newer treatments unless regulatory measures are implemented.
In March 2024, the US FDA granted orphan drug and pediatric exclusivity to CRESEMBA (isavuconazonium sulfate) for treating invasive Aspergillosis and invasive mucormycosis in pediatric patients.
The Aspergillosis market is expected to grow significantly during the forecast period, driven by the introduction of new therapies like Opelconazole and others.
In April 2024, Pulmocide Ltd. announced positive topline results from the OPERA-S Phase II trial, which evaluated inhaled opelconazole in lung transplant patients. The trial showed that opelconazole was well tolerated, with fewer adverse events and drug-drug interactions than standard care, effectively preventing and eradicating pulmonary Aspergillus and Candida infections.
In January 2024, TFF Pharmaceuticals revealed that it would present Phase II trial data on Voriconazole Inhalation Powder (TFF VORI) for treating invasive pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conference in Milan, Italy, highlighting advancements in the treatment of this severe fungal infection.
The total Aspergillosis market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
As per DelveInsight analysis, the Aspergillosis market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Aspergillosis Market Landscape
Aspergillosis Overview
Aspergillosis is a fungal infection caused by the Aspergillus species, most commonly *Aspergillus fumigatus*. It primarily affects individuals with weakened immune systems or pre-existing lung conditions, such as chronic obstructive pulmonary disease (COPD) or cystic fibrosis. The condition includes allergic fungal sinusitis, invasive aspergillosis, and chronic pulmonary aspergillosis. Allergic fungal sinusitis involves an immune response to the fungus in the sinuses, causing chronic inflammation and sinusitis. Invasive aspergillosis is a severe, potentially life-threatening form that can spread from the lungs to other organs, particularly in immunocompromised patients, such as those undergoing chemotherapy or living with advanced HIV/AIDS. Chronic pulmonary aspergillosis is a long-lasting lung infection that may develop from previous lung conditions.
Diagnosing aspergillosis involves a combination of clinical evaluation, imaging studies, and laboratory tests. Clinicians typically begin with a detailed medical history and physical examination, focusing on symptoms such as persistent cough, fever, and chest pain. Imaging techniques, especially high-resolution CT scans, are essential for identifying lung abnormalities, such as nodules or infiltrates, associated with aspergillosis.
Laboratory diagnosis includes culturing respiratory specimens or biopsies to identify Aspergillus species. Serological tests, such as the galactomannan antigen test, help diagnose invasive aspergillosis by detecting specific antibodies or antigens related to Aspergillus. Additionally, molecular techniques like polymerase chain reaction (PCR) can detect Aspergillus DNA in clinical samples. In cases such as allergic fungal sinusitis, nasal or sinus biopsies may be necessary. A combination of these diagnostic methods is often required to accurately identify the infection and determine its extent.
Despite advancements in Aspergillosis diagnostics, challenges remain, such as delays caused by time-consuming and complex testing. The sensitivity and specificity of existing tests, like antigen assays and cultures, are often inadequate, leading to potential misdiagnoses or treatment delays. There is a significant need for faster, non-invasive diagnostic methods with improved accuracy to enable early detection, particularly in asymptomatic or mild cases, and to improve patient outcomes.
Do you know the treatment paradigms for different countries? Download our Aspergillosis Market Sample Report
Aspergillosis Epidemiology Segmentation
DelveInsight’s Aspergillosis market report is prepared on the basis of an epidemiology model. It offers comprehensive insights to the Aspergillosis historical patient pools and forecasted Aspergillosis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Aspergillosis Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:
Aspergillosis Prevalence
Age-Specific Aspergillosis Prevalence
Gender-Specific Aspergillosis Prevalence
Diagnosed and Treatable Cases of Aspergillosis
Visit for more @ Aspergillosis Epidemiological Insights
Aspergillosis Market Outlook
Aspergillosis, a serious fungal infection, has various treatment options depending on the type and severity. Common treatments include azoles (such as voriconazole and posaconazole), echinocandins (like caspofungin), and polyenes (such as amphotericin B). Azoles are typically first-line therapies due to their effectiveness against multiple Aspergillus species, as they inhibit ergosterol synthesis, crucial for fungal cell membrane integrity. For severe or resistant cases, echinocandins are prescribed to disrupt glucan synthesis in the fungal cell wall. Polyenes, reserved for life-threatening infections, provide broad-spectrum activity. New therapies, like isavuconazole, are emerging with a more favorable side effect profile and improved convenience compared to traditional azoles.
The approval of new Aspergillosis therapies, such as PC945 and Olorofim, is expected to positively impact the market, though their success rates remain uncertain. In 2023, the Aspergillosis market in the US was valued at approximately USD 1,125 million, with an expected compound annual growth rate (CAGR) of 10% during the forecast period. The EU4 and the UK had a market size of around USD 866 million in 2023, with significant growth anticipated. The UK had the largest market share among EU countries, at approximately USD 325 million, while Spain had the smallest, at around USD 110 million. The market size is expected to change with the introduction of new therapies like Opelconazole (PC945) and Olorofim.
Aspergillosis Marketed Aspergillosis Drugs
CRESEMBA: Astellas Pharma/ Basilea Pharmaceutica International
Aspergillosis Emerging Aspergillosis Drugs
Olorofim (F901318): F2G
Opelconazole (PC945): Pulmocide
Aspergillosis Key Companies
Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, ImmuPharma, Takis, and others
For more information, visit Aspergillosis Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Aspergillosis Market Report:
11 Years Forecast
7MM Coverage
Descriptive overview of Aspergillosis, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Aspergillosis epidemiology in the 7MM
Aspergillosis marketed and emerging therapies
Aspergillosis companies
Aspergillosis market drivers and barriers
Table of Contents:
1 Aspergillosis Market Key Comprehensive Insights
2 Aspergillosis Market Report Introduction
3 Competitive Intelligence Analysis for Aspergillosis
4 Aspergillosis Market Analysis Overview at a Glance
5 Executive Summary of Aspergillosis
6 Aspergillosis Epidemiology and Market Methodology
7 Aspergillosis Epidemiology and Patient Population
8 Aspergillosis Patient Journey
9 Aspergillosis Treatment Algorithm, Aspergillosis Current Treatment, and Medical Practices
10 Key Endpoints in Aspergillosis Clinical Trials
11 Aspergillosis Marketed Therapies
12 Aspergillosis Emerging Therapies
13 Aspergillosis: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Aspergillosis
16 Aspergillosis Market Key Opinion Leaders Reviews
18 Aspergillosis Market Drivers
19 Aspergillosis Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Aspergillosis Epidemiology 2034
DelveInsight’s “Aspergillosis – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Aspergillosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Aspergillosis Pipeline 2024
“Aspergillosis Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Aspergillosis market. A detailed picture of the Aspergillosis pipeline landscape is provided, which includes the disease overview and Aspergillosis treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
